Our free daily oncology focused e-news service.
Subscribe» | Search Archives»
(Roche) July 31, 2015 - The approval is based on the benefit seen with the Perjeta regimen in achieving pathological complete response (pCR) in the neoadjuvant (use before surgery) treatment of HER2-positive early breast cancer (eBC); this is the first approval in Europe based on pCR, a clinical endpoint that has allowed Perjeta to be made available to people with this aggressive disease faster.
read corporate press release »
(Medscape Medical News) July 31, 2015 - In a finding that points to the overwhelming impact of out-of-pocket expenses in American cancer care, more than 30% of patients with advanced cancer rated their financial distress to be more severe than their physical, family, and emotional distress, according to a new study from Texas.
read article (free registration required) »
News Story Commentary By Academic and Community Oncologists
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.
OBR Job Board
Ipsen has 1 new job posted.
Dava Oncology has 1 new job posted.
Bayer has 7 jobs posted.
Seattle Genetics has 3 jobs posted.
Check out the OBR Job Board here.